NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Decrease in loss during the training process. by Muhammad Idrees (92773)

Screening for gHgLgO interaction partners reveals decreased binding of the gO249 mutant to cell surfaces. by Lena Thiessen (17605194)

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)

Explanation of condition nodes and decision nodes in the SCM, ordered by decreasing centrality. by Stella D. Juventia (19961247)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Each sample is a simulation of the entire assembly process for a scenario. Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Prolonged starvation leads to a delay in cell cycle re-entry and decrease in H3K27ac in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

“…See <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003525#pbio.3003525.s016" target="_blank">S5</a> and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003525#pbio.3003525.s017" target="_blank">S6 Tables</a> for mean values and statistical data and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003525#pbio.3003525.s020" target="_blank">S1 Data</a> for individual numerical values.…”

Knockdown of ATP2C1 results in a minor decrease of [Ca²⁺] in WPB. by Julian Terglane (12975565)